foxo4-dri human trial senolytic Buy 10mg | Third-Party Tested FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology Buy FOXO4 DRI Exceptional 99%+ Purity Third Party COA Included FOXO4 DRI Results: What to Expect (2026) The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $5.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17




